Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

CONCLUSION: Inetetamab demonstrates effectiveness with a manageable safety profile, offering a promising therapeutic option for HER2-positive breast cancer patients who have shown resistance to prior anti-HER2 treatments.PMID:37944341 | DOI:10.1016/j.breast.2023.103597

Source: Breast - November 9, 2023 Category: Cancer & Oncology Authors: Binliang Liu Ning Xie Can Tian Ronghua Feng Zhe-Yu Hu Jing Li Liping Liu Huawu Xiao Xiaohong Yang Mengsi Zeng Hui Wu Jun Lu Jianxiang Gao Xuming Hu Min Cao Zhengrong Shui Yu Tang Tao Wu Quchang Ouyang Source Type: research